Menu

Gilead

First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study

, , ,

AMBITION Study of Ambrisentan/Tadalafil Combination Therapy Versus Monotherapy Achieves Primary Endpoint of Time to First Clinical Failure Event Data Presented at the ERS International Congress 2014 MUNICH–(BUSINESS WIRE)–Sep. 8, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in […]

European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

, , ,

FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 25, 2014– Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Zydelig® (idelalisib 150 mg film-coated tablets), a first-in-class treatment for patients […]

Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries

, , ,

Agreement provides license for generic production of tenofovir alafenamide, an investigational agent for the treatment of HIV and chronic hepatitis B MELBOURNE, Australia–(BUSINESS WIRE)–Jul. 24, 2014– Gilead Sciences, Inc. (NASDAQ:GILD) announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead’s […]

U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma

, , ,

82 Percent Reduction in Risk of Disease Progression or Death When Combined with Rituximab Compared to Rituximab Alone in Patients with Relapsed Chronic Lymphocytic Leukemia FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 23, 2014– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Zydelig® (idelalisib) 150 mg tablets for the […]

Gilead Sciences’ Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire

, , ,

FOSTER CITY, Calif.–(BUSINESS WIRE)–Jan. 6, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Kevin Young CBE, Executive Vice President, Commercial Operations, has informed the company of his decision to retire, effective February 4th. Mr. Young will continue to work directly with Gilead’s management team as a senior advisor. Mr. Young joined Gilead in 2004 to lead the company’s global commercial […]

Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

, , ,

— High Cure Rates Observed with Single Tablet Regimen May Eliminate Interferon and Ribavirin from HCV Therapy for Genotype 1 Patients — — U.S. NDA Submission Planned for Q1 2014– FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 18, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from three Phase 3 clinical trials (ION-1, ION-2 and ION-3) evaluating the […]

Health Canada Issues Notice of Compliance for Sovaldi™ (Sofosbuvir) for the Treatment of Chronic Hepatitis C

, , ,

– Sovaldi Receives Marketing Authorization for Patients with Genotypes 1, 2, 3 or 4 HCV – – High Cure Rates (SVR 12) and Therapy Shortened to Just 12 Weeks for Many Patients – FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 16, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has issued a Notice of Compliance for Sovaldi™ (sofosbuvir) 400 […]

U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

, , , ,

— European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union — FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 13, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the single tablet HIV-1 regimen Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable […]

Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma

, , , ,

57 Percent Overall Response Rate and Median Duration of Response of 12.5 Months in Heavily Pre-Treated Patients Data Presented at American Society of Hematology Annual Meeting NEW ORLEANS, Dec 08, 2013 (BUSINESS WIRE) –Gilead Sciences, Inc. (Nasdaq: GILD) today announced results of a Phase 2 study (Study 101-09) evaluating idelalisib, an investigational oral inhibitor of PI3K […]

Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia

, , , ,

Data Presented at the 55th American Society of Hematology Annual Meeting NEW ORLEANS–(BUSINESS WIRE)–Dec. 7, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from a single-arm, open-label Phase 2 study evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase (Syk), for the treatment of patients with relapsed or refractory hematologic malignancies. The data show that […]

1 2 3